Analysts Offer Insights on Healthcare Companies: Biolinerx (BLRX), Steris (STE) and TRACON Pharmaceuticals (TCON)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biolinerx (BLRX – Research Report), Steris (STE – Research Report) and TRACON Pharmaceuticals (TCON – Research Report) with bullish sentiments.

Biolinerx (BLRX)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx today and set a price target of $19.00. The company’s shares closed last Wednesday at $1.06, close to its 52-week low of $1.05.

According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -33.5% and a 12.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Biolinerx has an analyst consensus of Moderate Buy, with a price target consensus of $19.00.

See the top stocks recommended by analysts >>

Steris (STE)

In a report released today, Michael Matson from Needham maintained a Buy rating on Steris, with a price target of $263.00. The company’s shares closed last Wednesday at $212.57.

According to TipRanks.com, Matson is a 3-star analyst with an average return of 0.7% and a 43.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Steris is a Strong Buy with an average price target of $269.33.

TRACON Pharmaceuticals (TCON)

H.C. Wainwright analyst Edward White reiterated a Buy rating on TRACON Pharmaceuticals today and set a price target of $12.00. The company’s shares closed last Wednesday at $1.78, close to its 52-week low of $1.62.

According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -29.2% and a 18.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

TRACON Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $10.40.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BLRX:

• Berenberg Bank Thinks AbSci’s Stock is Going to Recover
• Needham Thinks Vacasa’s Stock is Going to Recover
• H.C. Wainwright Thinks COMPASS Pathways’ Stock is Going to Recover
• Summit Wireless Technologies (WISA) Gets a Buy Rating from H.C. Wainwright
• H.C. Wainwright Thinks Xeris Pharmaceuticals’ Stock is Going to Recover